The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...
NEW YORK, NY / ACCESS Newswire / February 22, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback